FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2533902438> ?p ?o ?g. }

• W2533902438 endingPage "193" @default.
• W2533902438 startingPage "193" @default.
• W2533902438 abstract "193 Background: MVA-BN-PRO is an investigational prostate cancer immunotherapy comprising of a highly attenuated non-replicating vaccinia virus engineered to encode prostate specific antigen (PSA) and prostate acid phosphatase (PAP) proteins. Preclinical studies in mouse tumor models demonstrated vaccine-mediated induction of anti-PSA and PAP specific immune responses and anti-tumor activity. Results of the open-label multi-center evaluation in subjects with non-metastatic castration resistant prostate cancer are presented. Methods: Eligible subjects had documented prostate cancer with a rising PSA while on androgen suppression therapy and were chemotherapy naïve. Three cohorts of subjects were immunized subcutaneously receiving either 1, 2 or 4 injections of study drug (1 injection = 1×10 8 tissue culture infectious dose, TCID 50 ) at monthly intervals for three months (treatment). If the vaccinations were tolerated, re-treatment with an additional 3 monthly vaccinations was administered at the same dose. Responders, defined as subjects with stable or declining PSA at week 29 compared with baseline, were offered a 1-year extended treatment of up to 12 monthly vaccinations. Subjects were followed for one year after their last vaccination. The primary endpoint was safety. Immune responses (humoral and cellular) to MVA-BN-PRO including the transgenes PSA and PAP were assessed by the ELISA and ELISPOT assays, respectively. Exploratory analyses included anti-tumor activity as evaluated by serum PSA levels and progression by bone scan, per investigator determined, or death. Results: Twenty-four subjects were dosed. All subjects completed the initial 3 vaccinations (treatment) and 21 subjects received 6 vaccinations (re-treatment). Seven responders received additional vaccinations during the extended treatment. No dose-limiting toxicities were reported. There were no reported ≥ Grade 3 treatment-related adverse events (AE). The most common related AEs were Grade 1 or 2 general disorders and administration site reactions. Conclusions: MVA-BN-PRO was well tolerated. Results from immune analysis and clinical activity measured by PSA levels or radiological progression will be presented. Clinical trial information: NCT00629057." @default.
• W2533902438 created "2016-10-28" @default.
• W2533902438 creator A5010549946 @default.
• W2533902438 creator A5014985067 @default.
• W2533902438 creator A5025367991 @default.
• W2533902438 creator A5025577037 @default.
• W2533902438 creator A5027453053 @default.
• W2533902438 creator A5044789112 @default.
• W2533902438 creator A5070841954 @default.
• W2533902438 creator A5080278046 @default.
• W2533902438 creator A5083859146 @default.
• W2533902438 creator A5083990776 @default.
• W2533902438 creator A5088713549 @default.
• W2533902438 creator A5090431044 @default.
• W2533902438 creator A5090684168 @default.
• W2533902438 date "2013-02-20" @default.
• W2533902438 modified "2023-10-16" @default.
• W2533902438 title "Phase I dose escalation trial of MVA-BN-PRO in men with nonmetastatic castration-resistant prostate cancer." @default.
• W2533902438 doi "https://doi.org/10.1200/jco.2013.31.6_suppl.193" @default.
• W2533902438 hasPublicationYear "2013" @default.
• W2533902438 type Work @default.
• W2533902438 sameAs 2533902438 @default.
• W2533902438 citedByCount "0" @default.
• W2533902438 crossrefType "journal-article" @default.
• W2533902438 hasAuthorship W2533902438A5010549946 @default.
• W2533902438 hasAuthorship W2533902438A5014985067 @default.
• W2533902438 hasAuthorship W2533902438A5025367991 @default.
• W2533902438 hasAuthorship W2533902438A5025577037 @default.
• W2533902438 hasAuthorship W2533902438A5027453053 @default.
• W2533902438 hasAuthorship W2533902438A5044789112 @default.
• W2533902438 hasAuthorship W2533902438A5070841954 @default.
• W2533902438 hasAuthorship W2533902438A5080278046 @default.
• W2533902438 hasAuthorship W2533902438A5083859146 @default.
• W2533902438 hasAuthorship W2533902438A5083990776 @default.
• W2533902438 hasAuthorship W2533902438A5088713549 @default.
• W2533902438 hasAuthorship W2533902438A5090431044 @default.
• W2533902438 hasAuthorship W2533902438A5090684168 @default.
• W2533902438 hasConcept C104317684 @default.
• W2533902438 hasConcept C121608353 @default.
• W2533902438 hasConcept C126322002 @default.
• W2533902438 hasConcept C143998085 @default.
• W2533902438 hasConcept C147483822 @default.
• W2533902438 hasConcept C167672396 @default.
• W2533902438 hasConcept C185592680 @default.
• W2533902438 hasConcept C203014093 @default.
• W2533902438 hasConcept C203092338 @default.
• W2533902438 hasConcept C22070199 @default.
• W2533902438 hasConcept C2776490512 @default.
• W2533902438 hasConcept C2777701055 @default.
• W2533902438 hasConcept C2777760223 @default.
• W2533902438 hasConcept C2779053233 @default.
• W2533902438 hasConcept C2780192828 @default.
• W2533902438 hasConcept C2781356689 @default.
• W2533902438 hasConcept C2781406297 @default.
• W2533902438 hasConcept C40767141 @default.
• W2533902438 hasConcept C535046627 @default.
• W2533902438 hasConcept C55493867 @default.
• W2533902438 hasConcept C71924100 @default.
• W2533902438 hasConcept C8891405 @default.
• W2533902438 hasConceptScore W2533902438C104317684 @default.
• W2533902438 hasConceptScore W2533902438C121608353 @default.
• W2533902438 hasConceptScore W2533902438C126322002 @default.
• W2533902438 hasConceptScore W2533902438C143998085 @default.
• W2533902438 hasConceptScore W2533902438C147483822 @default.
• W2533902438 hasConceptScore W2533902438C167672396 @default.
• W2533902438 hasConceptScore W2533902438C185592680 @default.
• W2533902438 hasConceptScore W2533902438C203014093 @default.
• W2533902438 hasConceptScore W2533902438C203092338 @default.
• W2533902438 hasConceptScore W2533902438C22070199 @default.
• W2533902438 hasConceptScore W2533902438C2776490512 @default.
• W2533902438 hasConceptScore W2533902438C2777701055 @default.
• W2533902438 hasConceptScore W2533902438C2777760223 @default.
• W2533902438 hasConceptScore W2533902438C2779053233 @default.
• W2533902438 hasConceptScore W2533902438C2780192828 @default.
• W2533902438 hasConceptScore W2533902438C2781356689 @default.
• W2533902438 hasConceptScore W2533902438C2781406297 @default.
• W2533902438 hasConceptScore W2533902438C40767141 @default.
• W2533902438 hasConceptScore W2533902438C535046627 @default.
• W2533902438 hasConceptScore W2533902438C55493867 @default.
• W2533902438 hasConceptScore W2533902438C71924100 @default.
• W2533902438 hasConceptScore W2533902438C8891405 @default.
• W2533902438 hasIssue "6_suppl" @default.
• W2533902438 hasLocation W25339024381 @default.
• W2533902438 hasOpenAccess W2533902438 @default.
• W2533902438 hasPrimaryLocation W25339024381 @default.
• W2533902438 hasRelatedWork W1965945494 @default.
• W2533902438 hasRelatedWork W1997140918 @default.
• W2533902438 hasRelatedWork W2079491283 @default.
• W2533902438 hasRelatedWork W2349631909 @default.
• W2533902438 hasRelatedWork W2357951527 @default.
• W2533902438 hasRelatedWork W2611547332 @default.
• W2533902438 hasRelatedWork W28983714 @default.
• W2533902438 hasRelatedWork W3030041289 @default.
• W2533902438 hasRelatedWork W3154944633 @default.
• W2533902438 hasRelatedWork W87839233 @default.
• W2533902438 hasVolume "31" @default.
• W2533902438 isParatext "false" @default.
• W2533902438 isRetracted "false" @default.

• next